MXRA8 is an immune-relative prognostic biomarker associated with metastasis and CD8+ T cell infiltration in colorectal cancer

Colorectal cancer (CRC) is the second most common cause of cancer-related deaths worldwide. Tumor metastasis and CD8 T cell infiltration play a crucial role in CRC patient survival. It is important to determine the etiology and mechanism of the malignant progression of CRC to develop more effective...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in oncology Vol. 12; p. 1094612
Main Authors Tan, Lulu, Fu, Daan, Liu, Feng, Liu, Jia, Zhang, Yang, Li, Xin, Gao, Jinbo, Tao, Kaixiong, Wang, Guobin, Wang, Lin, Wang, Zheng
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 10.01.2023
Subjects
CD8+ T cell
colorectal cancer
immune infiltration
metastasis
MXRA8
Oncology
MXRA8
colorectal cancer
immune infiltration
metastasis
CD8+ T cell
Online AccessGet full text

Cover

More Information
Summary:Colorectal cancer (CRC) is the second most common cause of cancer-related deaths worldwide. Tumor metastasis and CD8 T cell infiltration play a crucial role in CRC patient survival. It is important to determine the etiology and mechanism of the malignant progression of CRC to develop more effective treatment strategies. We conducted weighted gene co-expression network analysis (WGCNA) to explore vital modules of tumor metastasis and CD8 T cell infiltration, then with hub gene selection and survival analysis. Multi-omics analysis is used to explore the expression pattern, immunity, and prognostic effect of MXRA8. The molecular and immune characteristics of MXRA8 are analyzed in independent cohorts, clinical specimens, and MXRA8 expression was strongly correlated with tumor malignancy, metastasis, recurrence, and immunosuppressive microenvironment. Furthermore, MXRA8 expression predicts poor prognosis and is an independent prognostic factor for OS in CRC. MXRA8 may be a potential immunotherapeutic and prognostic biomarker for CRC.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Edited by: Alessandro Passardi, Department of Medical Oncology (IRCCS), Italy
This article was submitted to Gastrointestinal Cancers: Colorectal Cancer, a section of the journal Frontiers in Oncology
These authors have contributed equally to this work
Reviewed by: Zhen Wang, Zhejiang University, China; Kai Zhang, Zhengzhou University, China
ISSN:2234-943X
2234-943X
DOI:10.3389/fonc.2022.1094612